Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oncology studies lack full disclosure of industry payments

Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.

Key clinical point: Financial disclosure statements in published oncology studies are often incomplete.

Major finding: Among study authors involved in oncology trials, 32% did not fully disclose payments from trial sponsors.

Study details: A comparison of financial disclosure statements in published studies with information from the Open Payments database. The researchers looked at studies that supported U.S. oncology drug approvals from Jan. 1, 2016, to Aug. 31, 2017.

Disclosures: The researchers reported having no financial disclosures.

Read the article.

Citation:

Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.

This Week's Must Reads

Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53

Study examines rehabilitative palliative care in cancer, Nottelmann L et al. 2018 Palliative and Supportive Care in Oncology Symposium Abstract 75

HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901

Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Must Reads in Practice Management

Oncology studies lack full disclosure of industry payments, Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA